Stepped-Care PCIT Model Leveraging Group and Individual Services

Date Added
June 25th, 2026
PRO Number
Pro00151557
Researcher
Rosmary Ros-Demarize

List of Studies


Keywords
ADD/ADHD, Autism, Children's Health, Pediatrics
Summary

The purpose of this research is to assess a stepped care model of a telehealth parenting program for children ages 2-6 years old with a neurodevelopmental diagnosis and behavior problems. Families will complete an online intake assessment, 6 group-based tele-health Parent-Child Interaction Therapy (PCIT) sessions, and an online post intervention assessment. Some families may receive additional individual virtual booster sessions and will complete a second online post assessment.

Institution
MUSC
Recruitment Contact
Alexandra Marsden
843-714-1352
autismresearch@musc.edu

Autism & Self-regulation: Tele-Assessment of Autonomic Psychophysiological correlates (ASAP)

Date Added
November 4th, 2025
PRO Number
Pro00146541
Researcher
Rosmary Ros-Demarize

List of Studies


Keywords
Autism, Children's Health
Summary

This study aims to evaluate the remote delivery of self-regulation assessments in young children with autism and their parents. Parents will complete online surveys. Parents and children will complete two virtual visits. At the second visit, participants will wear a heart rate monitor while completing study tasks. This study will inform research on behavioral therapies for children with autism.

Institution
MUSC
Recruitment Contact
Alexandra Marsden
843-714-1352
autismresearch@musc.edu

An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone in the Treatment of Pediatric Patients with Schizophrenia, Bipolar Disorder, or Autism Spectrum Disorder

Date Added
August 21st, 2025
PRO Number
Pro00140167
Researcher
Thomas Uhde

List of Studies


Keywords
Autism
Summary

Currently, there are no FDA-approved medications for the treatment of irritability associated with Autism Spectrum Disorder (ASD). This study is designed to look at the usefulness and safety of lumateperone (CAPLYTA) for the treatment of irritability associated with ASD among pediatric participants between the ages of 5 to 17 years. The study will last approximately 26 weeks and the participants will receive the study drug, lumateperone.

Institution
MUSC
Recruitment Contact
Jelissa Suarez
843-876-9262
suarezj@musc.edu



-- OR --